Porton Pharma Solutions Ltd.

Total Valuation

Porton Pharma Solutions Ltd. carries a market capitalization of 9.77B, placing it among publicly traded companies globally. Its enterprise value stands at 7.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Porton Pharma Solutions Ltd. currently has 545.46M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 2.23, and the price-to-book ratio stands at 2.41.

Enterprise Valuation

On an enterprise value basis, Porton Pharma Solutions Ltd. trades at an EV/EBITDA multiple of 56.03 and an EV/FCF ratio of 15.65. The EV/Sales ratio of 2.42 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 56.03 provides insight into valuation relative to core operating earnings.

Financial Position

Porton Pharma Solutions Ltd. maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.08, indicating elevated leverage, while an interest coverage ratio of 2.35 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Porton Pharma Solutions Ltd. has paid 49.68M in income taxes, reflecting an effective tax rate of 16.60.

Stock Price Statistics

Porton Pharma Solutions Ltd.'s stock has gained approximately 6.71021% over the past 52 weeks. The 50-day moving average sits at 16.73, while the 200-day moving average is 21.96.

Income Statement

Over the trailing twelve months, Porton Pharma Solutions Ltd. generated 3.28B in revenue and converted that into -90.66M in net income, yielding earnings per share of -0.36. EBITDA reached 141.54M, while operating income came in at 141.54M.

Balance Sheet

Porton Pharma Solutions Ltd. holds 1.54B in cash and equivalents against 1.98B in total debt, resulting in a net debt position of -62.82M. Total book value stands at 3.04B, with working capital of 1.50B providing operational flexibility.

Cash Flow

After subtracting -418.03M in capital expenditures, free cash flow totaled -418.03M - equivalent to -0.98 per share.

Margins

Porton Pharma Solutions Ltd. operates with a gross margin of 28.47, reflecting its pricing power and cost economics. The operating margin of 4.31 and net profit margin of -2.76 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -16.94 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Porton Pharma Solutions Ltd.'s most recent stock split took place on September 29, 2015 with a 2:3 split ratio.

Scores

Porton Pharma Solutions Ltd. posts an Altman Z-Score of 2.47, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.